We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Drug Companies Comment on Shortcomings in FDA Draft Guidance on Generic Topical Patches
Drug Companies Comment on Shortcomings in FDA Draft Guidance on Generic Topical Patches
Earlier this summer the FDA recommended a five-point scale to measure topical patch adhesion for drugmakers submitting abbreviated new drug applications (ANDA). However, the recommendations have only raised more questions.